Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 292Urinary Bladder Neoplasms 39Neoplasm Metastasis 35Carcinoma, Non-Small-Cell Lung 24Carcinoma, Transitional Cell 23Neoplasms 21Breast Neoplasms 20Lung Neoplasms 13Carcinoma, Renal Cell 13Ovarian Neoplasms 12Stomach Neoplasms 11Squamous Cell Carcinoma of Head and Neck 11Non-Muscle Invasive Bladder Neoplasms 10Melanoma 9Small Cell Lung Carcinoma 7Salivary Gland Neoplasms 7Prostatic Neoplasms, Castration-Resistant 7Head and Neck Neoplasms 7Esthesioneuroblastoma, Olfactory 7Esophageal Neoplasms 7Colorectal Neoplasms 7Urethral Neoplasms 6Uterine Cervical Neoplasms 5Triple Negative Breast Neoplasms 5Prostate Cancer Metastatic 5Pancreatic Neoplasms 5Metastatic Castration-resistant Prostate Cancer 5Kidney Neoplasms 5Adenocarcinoma 5Sarcoma 4

Interventions

tasquinimod 1masitinib 1Prednisone 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Castrate Resistant Prostate Cancer × Docetaxel × Genitourinary × Clear all
NCT03761225 2023-09-29

Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer

AB Science

Phase 3 Completed
714 enrolled
Genitourinary

Metastatic Castrate Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡